<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="768">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369365</url>
  </required_header>
  <id_info>
    <org_study_id>OnCoVID-19 Trial</org_study_id>
    <nct_id>NCT04369365</nct_id>
  </id_info>
  <brief_title>A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic</brief_title>
  <official_title>A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Matthias Preusser</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic treatment in cancer patients undergoing antineoplastic therapy during the
      COVID-19 pandemic.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">December 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections</measure>
    <time_frame>12 weeks after initiation of therapy</time_frame>
    <description>assessed by positive polymerase chain reaction (PCR) from routine nasal swabs (performed every 28 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of severe COVID-19 cases</measure>
    <time_frame>12 weeks after initiation of therapy</time_frame>
    <description>defined as combined endpoint of hospitalization rate or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of COVID-19 cases</measure>
    <time_frame>12 weeks after initiation of therapy</time_frame>
    <description>grading as outlined by the world health organization (WHO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>12 weeks after initiation of therapy</time_frame>
    <description>significant clinical and laboratory abnormalities according to CTCAE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of viral and bacterial infections</measure>
    <time_frame>12 weeks after initiation of therapy</time_frame>
    <description>other than COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with azithromycin-resistant bacterial strains in nasal swabs test</measure>
    <time_frame>12 weeks after initiation of therapy</time_frame>
    <description>Development of azithromycin-resistant bacterial strains as assessed by nasal swabs test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Arm A: Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly oral azithromycin 1500mg for a maximum of 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>weekly oral placebo for a maximum of 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 500 milligram (mg) oral Tablet</intervention_name>
    <description>weekly oral use</description>
    <arm_group_label>Arm A: Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>weekly oral use</description>
    <arm_group_label>Arm B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed cancer diagnosis

          -  Ongoing systemic antineoplastic treatment irrespective of application route

          -  Age ≥ 18 years

          -  Life expectancy of at least 3 months

          -  Adequate renal, cardiac and liver function

          -  Corrected QT time (QTc) ≤ 450 ms

          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt; 3

          -  Capable of understanding the study and giving informed consent

          -  Negative COVID-19 test at study entry as measured by routine testing

        Exclusion Criteria:

          -  Use of any investigational agent within 28 days prior to study start

          -  Patients with active opportunistic infections

          -  Pregnant or lactating women

          -  Women of childbearing potential and male subjects not willing to use adequate
             contraception methods during the study period

          -  Hypersensitivity to azithromycin or other macrolides

          -  Concurrent medication with ergotamine, theophylline, digitalis

          -  Inability to swallow tablets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthias Preusser, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>44450</phone_ext>
    <email>matthias.preusser@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marika Rosner</last_name>
    <phone>+43140400</phone>
    <phone_ext>44450</phone_ext>
    <email>marika.rosner@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AKH Vienna, Department for Internal Medicine I, Oncology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Preusser, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>44450</phone_ext>
      <email>matthias.preusser@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Marika Rosner</last_name>
      <phone>+43140400</phone>
      <phone_ext>44450</phone_ext>
      <email>marika.rosner@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Matthias Preusser</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

